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Abstract (150 words) 
 
Given the intuitive potential of stem cell therapy and limitations of current treatment options 
for progressive multiple sclerosis (MS), it is perhaps unsurprising that patients consider 
undertaking significant clinical and financial risks to access stem cell transplantation. 
However, while there is increasing evidence to support autologous haematopoietic stem 
cell transplanation (AHSCT) in aggressive relapsing remitting MS, interventions employing 
haematopoietic or other stem cells should otherwise be considered experimental and can 
be recommended only in the context of a properly regulated clinical study. 
Understandably, neurologists may lack familiarity with AHSCT procedures and specific 
requirements for quality assurance and safety standards as well as post-procedure 
precautions and follow up. Consequently they may feel ill-equipped to offer advice to 
patients. Here, we highlight important points for discussion in consultations with patients 
considering stem cell ‘tourism’ for MS.   
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Introduction 
 
Multiple Sclerosis (MS) is a chronic, immune-mediated, inflammatory disease of the 
central nervous system (CNS) causing demyelination and axonal loss with associated 
neurological disability. It affects approximately 100,000 people in the UK where it is the 
commonest cause of acquired neurological disability in young adults.[1] Although disease 
modifying treatments are available for patients with relapsing remitting MS, treatment 
options for patients with progressive disease are largely restricted to symptomatic 
therapies. Given the inadequacy of currently available treatment options, it is not surprising 
that patients with MS may seek experimental therapies and, if participation in regulated 
clinical trials is not possible or if they have firmly held views on the efficacy of a particular 
approach, they may explore alternative approaches.  
 
Direct-to-consumer advertising of unproven interventions, and accessibility of information 
via the internet have increased patient demand, but there are increasing concerns, 
particularly with respect to clinical and financial risks presented to patients - not to mention 
the reputation of stem cell research.[2, 3] To date, efforts to regulate this global problem 
have met with little success[4] and, whilst patient autonomy must be respected, clinicians 
also have a responsibility to discuss potential risks, and advise patients against 
interventions considered inappropriate, unproven and potentially harmful. However, while 
neurologists may understand the level of evidence for stem cell therapy, they may be less 
familiar with procedures and risks associated with transplantation, and with internationally-
agreed standards for transplant centres. Our aim is to provide practicing neurologists with 
an overview of the AHSCT process and a framework to assist when counselling patients 
considering stem cell ‘tourism’. 
 
Stem cell therapy for MS – what is the attraction? 
 
In AHSCT, haematopoietic stem cells (HSC) rescue patients from fatal bone marrow 
failure (aplasia) induced by myeloablative chemotherapy or radiotherapy. In the context of 
MS, the rationale for this type of stem cell treatment is to permit exposure to powerful 
immunoablative therapies, ‘re-setting’ the immune system. However, stem cell therapy has 
long been appreciated to hold promise for a wide range of conditions for which current 
treatments are sub-optimal or non-existent. The intuitive appeal of a ready source of cells 
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which can multiply, migrate and differentiate to repair damaged tissues has led to 
considerable hype and expectation[5] although, to date, stem cell therapy including 
AHSCT is integral to treatment of relatively few conditions outside haematology and 
oncology. More recently, research attention has shifted from a focus on the ‘pluripotency’ 
of stem cells to the potential benefit of harnessing non-canonical reparative properties 
including anti-inflammatory or immunomodulatory effects, neuroglial protective properties 
or angiogenesis. These functions may be effected via a range of mechanisms including 
paracrine activity and cell fusion.[6]  
 
It should be noted however, that irrespective of the mechanism(s) of effect, numerous 
technical challenges remain to be solved before the full clinical impact of AHSCT or other 
stem cell-based interventions can be realised. While advances can be made in the context 
of well-regulated clinical research, the process will necessarily be iterative if excessive 
morbidity and mortality are to be avoided.[7] 
 
Stem cell therapy 
 
Clarification of what is meant by ‘stem cell therapy’ is critical to any discussion regarding 
potential risks and benefits. A full review of the important consideration of cell source and 
summary of current stage of clinical translation is outwith the current remit (recently 
reviewed[8]). In summary however, cells may be isolated from the patient (autologous) or 
donated by others (allogeneic) and specific cell type must be considered. In AHSCT, 
haematopoietic stem cells (HSC) are key but there is increasing appreciation that 
additional cell populations may have regenerative potential. These include mesenchymal 
stromal cells (MSC) isolated from bone marrow or other sources e.g. adipose tissue. MSC 
have many attractive properties for cell-based therapy[6] but, as yet, clinical benefit has 
not been demonstrated in randomised, placebo-controlled trials in neurological diseases 
including MS.  
 
It is recognised that unscrupulous providers may target vulnerable patient populations 
marketing interventions that are unproven and potentially dangerous. This worldwide issue 
is proving difficult to regulate and requires ongoing collaboration between state regulators, 
patient advocacy groups, clinicians and scientists[9-11] but the importance of highlighting 
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to patients that regulated clinical research rarely, if ever, requires participants to pay for 
inclusion should not be underestimated. 
 
AHSCT 
 
AHSCT is a well-established therapeutic option in haemato-oncology. Replacing the 
haematological system goes hand in hand with regenerating a ‘new’ immune system, 
explaining its potential in auto-immune disease. However, treatment-related toxicity has 
restricted its use to only a small proportion of patients with highly aggressive, treatment-
refractory diseases including systemic sclerosis and systemic lupus erythematosus.[12] 
The mechanism(s) by which AHSCT exerts clinical effects in MS is not entirely certain but 
is likely to involve immunomodulation in favour of regulatory cells with suppression of pro-
inflammatory lymphocytes.[13]  
 
Such ‘re-setting’ must be preceded by attempts essentially to ‘remove’ the patient’s 
original immune system (‘conditioning’) before transplantation, and so AHSCT can be 
broken down into stages: stem cell collection, graft preparation and storage, conditioning 
regimen, and transplant delivery and engraftment (figure 1). 
 
HSC collection, graft preparation and storage 
Prior to collection, patients for AHSCT should be screened for herpes simplex virus, 
varicella zoster virus, human immunodeficiency virus, and the hepatitides. Although HSC 
comprise some 0.01% of nucleated cells in the marrow, they can restore all blood lineages 
following myeloablation[14]. The key marker used in clinical practice to predict functional 
engraftment is the peripheral CD34-positive cell count with a requirement for 2-3x106 
CD34-positive cells/kg body weight.[15] Until recently, autologous or allogeneic cells were 
isolated by bone marrow harvest involving multiple transcortical punctures of bone, usually 
posterior iliac crest, and aspiration of marrow under general anaesthesia. Increasingly 
however, cytokine-mediated mobilisation of cells into peripheral blood using low dose 
chemotherapy, granulocyte colony stimulating factor (G-CSF) and/or stem cell factor 
(SCF) followed by apheresis is employed. Unexpectedly, use of G-CSF alone may be 
associated with an MS flare, so it is frequently used in combination with corticosteroid 
therapy or cyclophosphamide.[16] Umbilical cord blood is an alternative cell source; 
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although the low CD34-positive cell dose previously restricted use of cord blood to 
children, outcomes in adults are now improving.[17]  
 
Following collection, cells may be stored without manipulation or be T cell depleted with 
the aim of further reducing autoreactivity following engraftment.[14, 18] Although HSC can 
be infused fresh, they are more commonly cryopreserved for storage. 
 
Conditioning regimen 
Patients undergoing AHSCT are exposed to a conditioning regimen designed to either 
eradicate malignant cells or to eliminate autoreactive cells in autoimmune diseases. The 
conditioning regimen is classified as ‘high’, ‘intermediate’ or ‘low’ intensity according to the 
degree of myeloablation; this predicts to a large degree the procedure-associated risk and 
morbidity. ‘High’ intensity regimens may include total body irradiation and/or myeloablative 
chemotherapy, frequently in combination with immune-depleting drugs such as anti-
thymocyte globulin, alemtuzumab or rituximab to further suppress autoreactive cells.[18] 
These are associated with improved outcomes in preclinical studies but increased 
transplant-related mortality in patients.[19, 20] ‘Low’ intensity regimens aim for 
lymphoablation only but may be of limited long-term efficacy. In European studies, the 
most frequently employed regimen is ‘BEAM’ - an ‘intermediate’ intensity regimen 
including carmustine, etoposide, cytarabine and melphalan, often followed by anti-
thymocyte globulin.[16]  
 
Transplant delivery and engraftment 
The HSC source is infused intravenously following exposure to the conditioning regimen 
and functional engraftment is expected to occur in approximately 2 weeks. Longer term 
immunological changes include a sustained inversion of CD4/CD8 ratio[21] and a broader 
clonal diversity in T cell receptor repertoire potentially making patients susceptible to 
opportunistic infections such as Pneumocystis jiroveci pneumonia,[22] although many 
centres recommend routine prophylaxis only while the CD3 lymphocyte count is <300x106 
cells/L. Post-transplantation, regular monitoring of full blood count including lymphocytes 
should be undertaken for at least 2 months to ensure sustained myeloid and platelet 
engraftment, and there should be a low index of suspicion to consider re-screening for 
herpes simplex virus, varicella zoster virus, human immunodeficiency virus if relevant 
symptoms emerge at any time point post-transplantation. 
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AHSCT for MS – what are the risks? 
 
The source and processing of cells for transplantation are critical determinants of the likely 
safety of the approach and each has potential advantages and disadvantages. With 
respect to specific risks of transplantation, autologous therapies are not associated with 
risks of immunosuppression or graft versus host disease which may complicate allogeneic 
transplants but autologous cells may have inherent deficits associated with either MS or its 
comorbidities.[23, 24] Additional risks include those associated with a bone marrow 
harvest performed under general anaesthetic or an MS flare following administration of a 
bone marrow mobilising agent. Furthermore, manipulation of cells ex vivo may be 
complicated by infection or cell transformation due to induction of genetic instability. 
Rarely, reactions to chemicals such as dimethyl sulfoxide (DMSO) used in 
cryopreservation may cause anaphylaxis.  
 
Overall however, the greatest risks are associated with myeloablative procedures due to 
neutropenic sepsis and haemorrhage in the context of thrombocytopenia; these contribute 
disproportionately to the estimated 2-3% risk of transplant-related mortality associated with 
AHSCT.[25] In general, patients with MS face similar regimen-related risks as patients 
undergoing transplantation for other indications but a number of complications are 
recognised to occur either more frequently or with greater severity including increased 
incidence of urinary tract infections, transient worsening of MS-related symptoms due to 
febrile neutropenia or infection (pseudorelapse), reactivation of human herpes viruses 
following CD34 selected grafts or anti-thymocyte globulin treatment as well as the additive 
effect on disability of neurotoxic conditioning regimens.[18] Late complications also include 
development of secondary autoimmunity; approximately 9% in all patients treated with 
autologous AHSCT for autoimmune disease.[26] Rituximab may be given concomitantly 
although can be associated with serious infections including viral reactivation and 
progressive multifocal leukoencephalopathy, albeit rarely.[27]  
 
Key consideration for patients considering health ‘tourism’ 
 
Given the significant risks of morbidity and mortality, AHSCT for patients with MS can, at 
present, be recommended only in the context of a properly regulated clinical study or trial. 
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Patients must also consider potential implications of travelling in the immediate period 
following myeloablative procedures when they may be thrombocytopenic or significantly 
immunosuppressed. Furthermore, AHSCT or involvement in unregulated experimental 
procedures is highly likely to disbar patients from future participation in clinical trials.  
 
The degree of regulation to which transplant centres are subject varies around the world 
but patients should be aware that internationally-agreed standards exist. Centres 
conducting AHSCT should have accreditation with the International Society for Cellular 
Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) 
via the Joint Accreditation Committee (JACIE). Outcome data should be reported to EBMT 
or another transplant registry. An additional transplant centre consideration is whether they 
are aware of specific needs and risks faced by those with MS; outcomes are likely to be 
better in those centres with greater familiarity treating patients with MS.[18] 
 
For those determined to travel to access AHSCT offered on a commercial basis, we 
recommend they review the provider’s reputation and safety record with care. We advise 
review of the EBMT/JACIE patient guidance[28, 29] and our additional recommendations 
are: 
1. The centre must have JACIE accreditation and it is essential that outcome data are 
reported to EBMT or another transplant registry. The experience of the centre in 
treating patients with MS should be noted. 
2. Transplant centres must perform a rigorous pre-transplant assessment of the 
individual's suitability and fitness for the procedure and discuss any procedure-
associated risks in the context of MS and additional co-morbidities. 
3. The patient should check in advance whether the clinic is adequately prepared to 
handle emergencies such as a serious allergic reaction or cardiac arrest, and 
enquire about contingency plans should complications occur.  
4. Transplant centres must provide recommendations regarding post-procedure travel 
arrangements in advance of treatment and agree to issue a discharge summary to 
the regular care provider including details of the conditioning regimen and cell 
infusion as well as any complications encountered.  
5. Specific requirements for follow up and monitoring must be provided by the 
transplant centre together with information regarding potential risks of treatment in 
the immediate future and longer term.  
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For patients considering other stem cell ‘treatments’, inclusion can only be recommended 
in the context of a regulated clinical trial and particular caution is required when 
participants are required to pay for an intervention that is not approved by the relevant 
national regulatory authority. 
 
Conclusions 
 
The frustration experienced by patients with MS in the context of slow progress with the 
development of novel and effective treatments, particularly for progressive disease, is 
understandable. However, the urge to ‘do something’ can encourage people to consider 
unproven interventions of uncertain benefit despite their often-significant risk profile which 
may include death and worsening disability. Wherever possible, patients should be 
encouraged to participate in well-regulated, carefully conducted clinical trials and registry 
studies where adverse events are closely monitored and where both adequate clinical 
back-up should complications be encountered and good follow up care are available. 
Ultimately, trials will establish whether AHSCT is effective and will inform improvements in 
both the procedure and patient selection. Patients who can consent to travel for the 
purpose of accessing direct-to-consumer treatments of uncertain benefit should be 
carefully advised of the potential risks, preferably in writing and, where there are concerns 
regarding capacity for consent, safeguarding measures should be taken.  
 
Key points 
 
1. AHSCT carries risk of significant morbidity and mortality in patients with MS, the 
more so when conducted in centres outside internationally agreed regulatory 
processes. It can be considered in the context of aggressive relapsing and remitting 
MS but the benefit of AHSCT is far from clear in progressive MS 
2. Those patients who pursue AHSCT on a direct-to-consumer basis, should ensure 
that the centre conforms to internationally-agreed standards 
3. Due care must be given to travel arrangements and follow up post-procedure, 
particularly for those who have received myeloablative conditioning regimens  
4. Aside from AHSCT in carefully defined circumstances and settings, no form of stem 
cell ‘treatment’ for MS can be recommended at present outside the context of a 
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properly regulated clinical trial and participants should not be expected to pay for 
inclusion. 
  
Figure Legends 
 
Figure 1 Autologous haematopoietic stem cell transplantation 
Schematic illustrating stages of AHSCT including mobilisation, collection, conditioning, 
storage and infusion. 
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